News | December 07, 2023
Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
